Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
N/A
Saved in:
Published in | Skin (Milwood, N.Y.) Vol. 6; no. 6; p. s49 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
16.11.2022
|
Online Access | Get full text |
Cover
Loading…
Summary: | N/A |
---|---|
ISSN: | 2574-1624 2574-1624 |
DOI: | 10.25251/skin.6.supp.49 |